UNCOVERED: 2 - Caught on Camera

Check Out What Whales Are Doing With NVAX

Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · May 9, 2022

How Novavax Stock Looks Headed Into Q1 Earnings

Novavax, Inc. (NASDAQ: NVAX) is set to print its first-quarter financial results after the market close on Thursday. The stock was trading more than 6% lower, at one point, heading into the event.

Benzinga · May 9, 2022

Novavax Seeks Approval For COVID-19 Shot Among Adolescents In Britain

Novavax Inc (NASDAQ:NVAX) filed an application with Britain's drugs regulator for the authorization of its COVID-19 vaccine among adolescents aged 12 and older. Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults. Novavax's submission includes data from a late-stage trial in the U.S., where the vaccine showed 80% efficacy among…

Benzinga · May 5, 2022

Why Novavax Shares Are Rising

Shares of vaccine companies, including Novavax, Inc. (NASDAQ: NVAX), are trading higher amid COVID-19 concerns due to rising cases in China.

Benzinga · Apr 25, 2022

Moderna vs. Novavax: Which Stock is a Better Investment?

The biotech industry is playing a crucial role in fighting against COVID-19 and is also making significant progress in developing cures for several other diseases with the help of advanced technologies. So, biotech companies Moderna (MRNA) and Novavax (NVAX) are well-positioned to continue benefiting from the industry’s solid growth prospects.…

StockNews.com · Apr 21, 2022

Novavax's COVID-19/Influenza Combo Vaccine Shows Immunogenicity In Early-Study

Novavax Inc (NASDAQ:NVAX) has announced initial results from the Phase 1/2 trial of its COVID-Influenza Combination Vaccine (CIC), combining the COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.  The CIC trial demonstrated that the combination vaccine is feasible, well-tolerated, and immunogenic. The safety and tolerability profile of the combination vaccine was consistent…

Benzinga · Apr 20, 2022

If You Invested $100 In Novavax 5 Years Ago, Here's How Much You Would Have Today

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 13.94% on an annualized basis producing an average annual return of 27.26%. Currently, Novavax has a market capitalization of $4.14 billion.

Benzinga · Apr 19, 2022

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares are trading lower Tuesday. The stock fell to new 52-week lows early in the session, but has since recovered.

Benzinga · Apr 19, 2022

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

Benzinga · Apr 18, 2022

Novavax's COVID-19 Vaccine Approved In Switzerland

Swissmedic, the Swiss Agency for Therapeutic Products, has granted conditional marketing authorization for Novavax Inc's (NASDAQ:NVAX) Nuvaxovid COVID-19 Vaccine for individuals 18 years of age and older.  The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine authorized for use in Switzerland. The Swissmedic decision was based on two pivotal Phase 3 clinical…

Benzinga · Apr 13, 2022